Mangoceuticals Share Price Today

Mangoceuticals closes $500,000 offering at 74% premium to market price

Closed registered direct offering of ~$500,000 at $0.75 per unit. Pricing represented a 74% premium to recent closing price of $0.43. Follows $2.5 million strategic investment commitment in MangoRx IP Holdings. Subsidiary received $1.75 million with remaining $750,000 due by Nov 28, 2026. Parent-level financing provides working capital without subsidiary equity dilution.

Mangoceuticals shares fall 12% after hours despite $2.5 million subsidiary investment

Mangoceuticals shares fell 12.24% to $0.42 in after-hours trading. Subsidiary MangoRx IP Holdings secured $2.5 million in strategic investment. Initial tranche of $1.75 million received; no dilution to public shareholders. Stock down 78.06% over the past year with market cap at $10.32 million.

Mangoceuticals, Nuclea Energy terminate deal after failing to raise $15M PIPE

Mangoceuticals and Nuclea Energy terminated their business combination agreement on August 19, 2026. The deal collapsed due to failure to raise the minimum $15 million in PIPE financing by August 21, 2026. Each party will bear its own costs and expenses related to the transaction. Mutual releases were exchanged, excluding liability for willful breaches prior to termination.

Halper Sadeh probes Mangoceuticals merger for shareholder fairness

Halper Sadeh LLC is investigating the Mangoceuticals-Nuclea Energy merger for potential fiduciary breaches. The firm cites concerns over insider benefits, limited competing offers, and inadequate disclosure, urging shareholders to contact them regarding their rights.

Nuclea Energy Signs MoU With New Mining To Study Modular Reactor Feasibility

Nuclea Energy signed a non-binding MoU with New Mining Co. to study modular reactor deployment for 30-100 MWe data center loads. Nuclea provides technical advisory while New Mining supplies site data. The deal supports Nuclea's pending merger with Mangoceuticals for Nasdaq listing.

Mangoceuticals shares jump 49% after Nuclea signs Utah nuclear deal

Mangoceuticals stock surged nearly 50% after hours as its merger partner Nuclea Energy USA signed an MOU with Utah to site a nuclear test reactor for the Morpheus microreactor. The company also received a Nasdaq extension until Feb 1, 2027, to meet bid price requirements.